Table 3. Efficacy and Safety Outcomes in Weighted Cohorts.
| Outcomes | Patients, No. | Events, No. | Person-years | Events per 100 person-years | Hazard ratio (95% CI) | P value |
|---|---|---|---|---|---|---|
| VTE recurrence | ||||||
| LMWH | 4607 | 398 | 1002.13 | 39.76 | 1.47 (1.14-1.90) | .003 |
| Warfarin | 4556 | 456 | 1526.48 | 29.89 | 1.46 (1.13-1.87) | .003 |
| DOAC | 4762 | 332 | 1609.44 | 20.62 | 1 [Reference] | NA |
| All-cause mortality | ||||||
| LMWH | 4607 | 225 | 1060.8 | 21.18 | 1.61 (1.15-2.25) | .005 |
| Warfarin | 4556 | 221 | 1627.76 | 13.59 | 1.19 (0.85-1.68) | .31 |
| DOAC | 4762 | 193 | 1696.33 | 11.36 | 1 [Reference] | NA |
| Hospitalization for major bleeding | ||||||
| LMWH | 4607 | 277 | 1035.84 | 26.73 | 2.27 (1.62-3.20) | <.001 |
| Warfarin | 4556 | 179 | 1609.61 | 11.1 | 1.12 (0.78-1.61) | .53 |
| DOAC | 4762 | 166 | 1681.52 | 9.88 | 1 [Reference] | NA |
| GI bleeding | ||||||
| LMWH | 4607 | 152 | 1041.21 | 14.64 | 1.72 (1.12-2.62) | .01 |
| Warfarin | 4556 | 119 | 1615.82 | 7.38 | 1.03 (0.67-1.59) | .89 |
| DOAC | 4762 | 121 | 1685.12 | 7.17 | 1 [Reference] | NA |
| Intracranial bleeding | ||||||
| LMWH | 4607 | 62 | 1058.49 | 5.88 | 2.72 (1.24-5.97) | .01 |
| Warfarin | 4556 | 31 | 1625.72 | 1.93 | 1.04 (0.45-2.45) | .92 |
| DOAC | 4762 | 31 | 1694.92 | 1.84 | 1 [Reference] | NA |
Abbreviations: DOAC, direct oral anticoagulants; GI, gastrointestinal; LMWH: low-molecular-weight heparin; NA, not applicable; VTE, venous thromboembolism.